Compound ID | 730
Synonym(s): CB-182804 | CB 182804
Class: Polymyxin
| Agent Type: | Semisynthetic; Direct acting; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Membrane-active agent |
| Target Pathogen: | Active against Escherichia coli, Klebsiella pneumoniae, Enterobacter, Acinetobacter, and Pseudomonas aeruginosa |
| Description: | A polymyxin analogue; lower efficiency in mouse septicaemia model than polymyxin B against Gram negatives but was more tolerable in cynomolgus monkeys |
| Institute where first reported: | Cubist Pharmaceuticals (Merck & Co, USA); BioSource Pharmaceuticals (Spring Valley, NY, USA) |
| Year first mentioned: | 2010 |
| Highest development stage: | Phase 1 |
| Development status: | Inactive |
| Reason dropped: | Showed toxicity issues |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/52918383 |
| Guide to Pharmacology: | CB-182804 |
| Citations: |
|